Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.33 |
| ▸ | ESR1 | P03372 | 8/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.32 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928183 | 0.79 | CRBN (0.42) | NPC1RAB9ASMN1; SMN2FFAR4CXCR2 | |
| SCHEMBL18275266 | 0.79 | METAP2 (0.38) | LMNAMAPK1CYP3A4CYP2C9CXCR2 | |
| SCHEMBL796489 | 0.77 | ALDH1A1 (0.57) | TP53CYP2C9CXCR2KDM6BKDM4A | |
| SCHEMBL20266094 | 0.76 | FFAR4 (0.34) | FFAR4 | |
| SCHEMBL850711 | 0.73 | CHRNB2 (0.42) | NPC1LMNARAB9ASMN1; SMN2ESR2 | |
| SCHEMBL15633074 | 0.72 | DDB1 (0.33) | GRIN2BOPRM1DEGS1 | |
| SCHEMBL24136402 | 0.71 | GRIN2B (0.39) | GRIN2B | |
| SCHEMBL24010681 | 0.71 | NPC1 (0.43) | NPC1LMNATP53MAPK1RAB9A | |
| SCHEMBL13535000 | 0.70 | KDM4E (0.47) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL797147 | 0.70 | CRBN (0.54) | NPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126350-B1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2018-07-04 | — | — | EP | disclosed |
| US-9908868-B2 | Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2018-03-06 | — | — | US | disclosed |
| EP-3126350-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2017-01-26 | — | — | US | disclosed |
| CN-106164068-A | Isoindolinone compounds as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions | 赛诺菲 | 2016-11-23 | — | — | CN | disclosed |
| EP-2906550-B1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI SA (FR) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015150565-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-10-08 | — | — | WO | disclosed |
| EP-2906550-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8853412-B2 | Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| WO-2014056938-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2014-04-17 | — | — | WO | disclosed |
| US-20140099333-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | SANOFI (FR) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022182-A1 | ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | NPC1 132/4885LMNA 2772/4885TP53 4320/4885 |
| US-20140099333-A1 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | GPR119, GPR65, GPR88 | NPC1 459/4885LMNA 2917/4885TP53 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.